DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Cromwell Holdings LLC

by · The Cerbat Gem

Cromwell Holdings LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,151 shares of the medical device company’s stock after selling 169 shares during the quarter. Cromwell Holdings LLC’s holdings in DexCom were worth $79,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Nia Impact Advisors LLC lifted its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company’s stock worth $766,000 after purchasing an additional 140 shares during the last quarter. Level Four Advisory Services LLC lifted its position in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock worth $1,026,000 after purchasing an additional 150 shares during the last quarter. Covestor Ltd lifted its position in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company’s stock worth $86,000 after purchasing an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on DXCM shares. Canaccord Genuity Group upped their price target on DexCom from $103.00 to $106.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. The Goldman Sachs Group started coverage on DexCom in a report on Friday, May 30th. They issued a “buy” rating and a $104.00 price target for the company. Mizuho started coverage on DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target for the company. Finally, Citigroup reaffirmed a “buy” rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.50.

Check Out Our Latest Stock Analysis on DXCM

DexCom Trading Up 0.7%

Shares of DXCM opened at $85.46 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.19. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The stock has a 50 day simple moving average of $84.31 and a 200-day simple moving average of $79.97. The stock has a market cap of $33.51 billion, a PE ratio of 63.78, a PEG ratio of 1.81 and a beta of 1.44.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm’s revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $85.06, for a total transaction of $124,697.96. Following the sale, the executive vice president directly owned 108,155 shares in the company, valued at $9,199,664.30. This represents a 1.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 in the last 90 days. Insiders own 0.32% of the company’s stock.

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).